Treatment response (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
Tricyclic antidepressants showed no clear difference in treatment response (post‐treatment score on self report and… compared with another medication (low certainty).
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anxiety · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment response (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional disability and quality of life (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anxiety · somatoform disorders in adults
1 finding from 1 review
Withdrawals due to adverse events · somatoform disorders in adults
New‐generation antidepressants showed no clear difference in adverse effects (drop‐outs due to adverse effects) compared with placebo (low certainty).
1 finding from 1 review
Treatment response (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
It is very uncertain whether new‐generation antidepressants changes treatment response (post‐treatment score on self report and… compared with placebo (very low certainty).
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults
1 finding from 1 review
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) · somatoform disorders in adults
1 finding from 1 review
Acceptability · somatoform disorders in adults
New‐generation antidepressants showed no clear difference in acceptability (all‐cause drop‐outs) compared with placebo (low certainty).
1 finding from 1 review
Repetition of SH at last · adults who engage in SH
Newer generation antidepressants showed no clear difference in repetition of SH at last compared with placebo (low certainty).
1 finding from 1 review
Reduction of TTM symptom severityNIMH Trichotillomania Severity Scale (NIMH‐TSS) · adults with trichotillomania
1 finding from 1 review
Dropouts due to adverse events · adults with trichotillomania
It is very uncertain whether TCAs with predominantly SRI actions changes tolerability of treatment ‐ dropouts due to adverse eventsdDropout… compared with placebo (very low certainty).
1 finding from 1 review
Treatment responseaPhysician‐rated Clinical Progress Scale · adults with trichotillomania
1 finding from 1 review
Reduction of TTM symptom severityNIMH Trichotillomania Severity Scale (NIMH‐TSS) · adults with trichotillomania
1 finding from 1 review
Withdrawals due to adverse events · adults with trichotillomania
1 finding from 1 review
Repetition of SH at post‐intervention · self‐harm in adults
It is very uncertain whether newer generation antidepressants (NGAs) changes repetition of SH by post‐intervention (NGA class)№ of participants:… compared with placebo (very low certainty).
3 findings from 1 review
OR 0.59 [0.29, 1.19]
Studies not reported
Very low
OR 0.67 [0.18, 2.41]
Studies not reported
Very low
OR 0.55 [0.24, 1.29]
Studies not reported
Low
Reduction in physical signs Decrease in seizure frequency End of treatment · people with conversion disorder according to DSM‐IV or ICD‐10 criteria
1 finding from 1 review